TR201009394A2 - Improved montelukast formulations. - Google Patents

Improved montelukast formulations.

Info

Publication number
TR201009394A2
TR201009394A2 TR2010/09394A TR201009394A TR201009394A2 TR 201009394 A2 TR201009394 A2 TR 201009394A2 TR 2010/09394 A TR2010/09394 A TR 2010/09394A TR 201009394 A TR201009394 A TR 201009394A TR 201009394 A2 TR201009394 A2 TR 201009394A2
Authority
TR
Turkey
Prior art keywords
improved
montelukast
formulations
montelukast formulations
counteract
Prior art date
Application number
TR2010/09394A
Other languages
Turkish (tr)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2010/09394A priority Critical patent/TR201009394A2/en
Priority to PCT/TR2011/000245 priority patent/WO2012064303A2/en
Priority to PCT/TR2011/000244 priority patent/WO2012064302A2/en
Priority to PCT/TR2011/000246 priority patent/WO2012064304A2/en
Publication of TR201009394A2 publication Critical patent/TR201009394A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Abstract

Mevcut buluş, montelukast ve/veya farmasötik kabul edilebilir bir tuzunu içeren formülasyonlarında kullanılan yardımcı maddelerin etken madde üzerindeki olumsuz etkilerini gidermek üzere tasarlanmış bileşimlerle ilgilidir.The present invention relates to compositions designed to counteract the adverse effects of excipients used in their formulations containing montelukast and / or a pharmaceutically acceptable salt thereof on the active ingredient.

TR2010/09394A 2010-11-11 2010-11-11 Improved montelukast formulations. TR201009394A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
TR2010/09394A TR201009394A2 (en) 2010-11-11 2010-11-11 Improved montelukast formulations.
PCT/TR2011/000245 WO2012064303A2 (en) 2010-11-11 2011-11-03 Improved montelukast combinations
PCT/TR2011/000244 WO2012064302A2 (en) 2010-11-11 2011-11-03 Improved montelukast formulations
PCT/TR2011/000246 WO2012064304A2 (en) 2010-11-11 2011-11-03 Combinations comprising montelukast

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/09394A TR201009394A2 (en) 2010-11-11 2010-11-11 Improved montelukast formulations.

Publications (1)

Publication Number Publication Date
TR201009394A2 true TR201009394A2 (en) 2012-06-21

Family

ID=45464073

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/09394A TR201009394A2 (en) 2010-11-11 2010-11-11 Improved montelukast formulations.

Country Status (2)

Country Link
TR (1) TR201009394A2 (en)
WO (3) WO2012064303A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677649C2 (en) * 2013-02-21 2019-01-18 Глэнмарк Фармасьютикалс Лимитед Pharmaceutical compositions of montelucast and levocetirisine
KR102226833B1 (en) * 2013-06-28 2021-03-12 한미약품 주식회사 Complex granule formulation having improved stability comprising levocetirizine and montelukast
CN104666302B (en) * 2013-11-27 2017-06-30 北京韩美药品有限公司 Composition and preparation method thereof, oral liquid and preparation method thereof
CN103655497B (en) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 A kind of Montelukast Sodium oral disnitegration tablet and preparation method thereof
CN104840427B (en) * 2014-02-13 2017-09-29 长春海悦药业股份有限公司 A kind of pharmaceutical composition containing Menglusitena
EP2949321A1 (en) * 2014-05-26 2015-12-02 Sanovel Ilac Sanayi ve Ticaret A.S. Multilayer formulations of fexofenadine and montelukast

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0480717B1 (en) 1990-10-12 1998-04-15 Merck Frosst Canada Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
ES2342727T3 (en) 2006-02-09 2010-07-13 Teva Pharmaceutical Industries Ltd. STABLE PHARMACEUTICAL FORMULATIONS OF MONTELUKAST SODICO.
WO2009122187A2 (en) * 2008-04-03 2009-10-08 Cipla Limited Pharmaceutical composition
TR200806298A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Pharmaceutical formulation
US20110189274A1 (en) 2008-10-06 2011-08-04 Swati Mukherjee Stable Pharmaceutical Compositions Of Montelukast Or Its Salts Or Solvates Or Hydrates
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations

Also Published As

Publication number Publication date
WO2012064304A2 (en) 2012-05-18
WO2012064304A3 (en) 2012-08-09
WO2012064302A3 (en) 2012-07-19
WO2012064302A2 (en) 2012-05-18
WO2012064303A3 (en) 2012-07-19
WO2012064303A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
MX2021000550A (en) Tofacitinib oral sustained release dosage forms.
PH12016500024A1 (en) Bromodomain inhibitor
MX2013001677A (en) Stable formulations of linaclotide.
EA201201263A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DAGIGATRAN ETEXYLATE
MX2015008627A (en) Boronic acid derivatives and therapeutic uses thereof.
EA201401351A1 (en) DERIVATIVES OF BENZIMIDAZOL-PROLINE
EA201270741A1 (en) ORAL COMPOSITIONS AND LIPOPHYL SALTS OF METHylNALTREX
EA201190145A1 (en) PHARMACEUTICAL COMPOSITIONS, CONTAINING THE BASIS OF THE EXTENSION OR THE ITS PHARMACEUTICALLY ACCEPTABLE SALTS OF THE ACCESSION OF THE ACID, AND METHODS OF THEIR COOKING
EA201390662A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DUTASTERIDE
EA201201050A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
UA115357C2 (en) Pyridin-4-yl derivatives
CY1115556T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT INCLUDES DAVIGATRAN
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
TR201009394A2 (en) Improved montelukast formulations.
EA201400822A1 (en) DERIVATIVES OF HETEROCYCLIC AMIDES AS AN ANTAGONISTS OF P2HRECEPTOR
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
EA201492029A1 (en) N-ETHYL-4-HYDROXYL-1-METHYL-5- (METHYL (2,3,4,5,6-PENTAHYDROXYGEXYL) AMINO) -2-OXO-N-PHENYL-1,2-DIHYDROCHINOLIN-3-CARBOXAMIDE
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
UA109804C2 (en) 2-methoxypyridine-4-yl derivatives
EP2611799A4 (en) Pharmaceutical compositions of linezolid
TR201803451T4 (en) OLMESARTAN FORMULATIONS.
TR200909785A1 (en) Pharmaceutical compositions containing cefdinir as the active agent.
TR201007926A1 (en) Prasugrel tablet formulations.
TR201009399A2 (en) Rapidly soluble effervescent rosuvastatin formulations.
TR201100152A2 (en) Effervescent compositions containing amlodipine.